Recent Posts

News, NGS, oncology
Congenica awarded European contract to develop NGS analysis workflow in oncology
Posted 6th December 2022

Congenica awarded European contract to develop NGS analysis workflow in oncology

Read More
Blog , NGS , GRCh38
Making the jump from GRCh37 to GRCh38
Posted 12th November 2021

Making the jump from GRCh37 to GRCh38

Read More
Blog , poster , prenatal , INGENIOUS , NGS
Improved Next Generation Sequencing for Ultrasound Abnormalities (INGENIOUS)
Posted 17th May 2021

Improved Next Generation Sequencing for Ultrasound Abnormalities (INGENIOUS)

Read More
1
News , NGS , oncology
Congenica awarded European contract to develop NGS analysis workflow in oncology
Posted 6th December 2022

Congenica awarded European contract to develop NGS analysis workflow in oncology

Read More
Blog , NGS , GRCh38
Making the jump from GRCh37 to GRCh38
Posted November Nov 12th 2021

Making the jump from GRCh37 to GRCh38

Read More
Blog , poster , prenatal , INGENIOUS , NGS
Improved Next Generation Sequencing for Ultrasound Abnormalities (INGENIOUS)
Posted May May 17th 2021

Improved Next Generation Sequencing for Ultrasound Abnormalities (INGENIOUS)

Read More
1
CE 60px-Conformité_Européenne - WHITE27001 RGB Tick 60x60 Congenica UL® ISO 13485:2016 A28485 HIPAA Compliance

Copyright © 2022 Congenica Ltd. Company number: 8273616 Registered in England and Wales

Congenica is available as a CE Marked IVD clinical decision support platform for clinical diagnostic use for inherited genetic disorders in the UK and EU, Iceland, Lichtenstein, Norway, Switzerland and Turkey. In all other countries, ensuring compliance with relevant local, national and international clinical laboratory regulations is the responsibility of the laboratory.